IP Library Granted Patent US 11,141,412
Granted Patent B2
US 11,141,412 · App. 16/535,107 · Granted Oct 12, 2021

Analogs of pridopidine, their preparation and use

Inventors: Malle Schmidt (Tallinn, EE); Malle Pari (Tallinn, EE); Marit Laos (Tallinn, EE); Ants Maasalu (Tallinn, EE); Kalle Kaljuste (Tallinn, EE)
Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
A61K31/451C07D211/24C07D211/42C07D211/52G01N30/88G01N2030/8872
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,141,412
App. No.
16/535,107
Granted
Oct 12, 2021
Kind
B2
Abstract

This invention provides an isolated compound having the structure: or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.

Claims (28)

1. A pharmaceutical composition comprising pridopidine or salt thereof and compound (1) or salt thereof

and one or more excipients.

2. A pharmaceutical composition comprising pridopidine salt and compound (1) or salt thereof

and one or more excipients.

3. A pharmaceutical composition comprising pridopidine or salt thereof and combination of compound (1) or salt thereof and compound (4) or salt thereof

4. A pharmaceutical composition comprising pridopidine or salt thereof and at least one of compounds 1-8 or salts thereof;

5. The composition of claim 1 , wherein the composition comprises pridopidine salt, wherein the salt is hydrochloride, hydrobromide, nitrate, perchlorate, phosphate, sulphate, formate, acetate; aconate, ascorbate, benzenesulphonate, benzoate cinnamate, citrate, embonate, enantate, fumarate, glutamate, glycolate, lactate, maleate, malonate, mandelate, methane-sulphonate, naphthalene-2-sulphonate, phthalate, salicylate, sorbate, stearate, succinate, tartrate or toluene-p-sulphonate salt.

6. The composition of claim 1 , wherein the composition comprises pridopidine salt, wherein the salt is hydrochloride salt.

7. The composition of claim 3 , wherein the composition comprises pridopidine salt, wherein the salt is hydrochloride, hydrobromide, nitrate, perchlorate, phosphate, sulphate, formate, acetate, aconate, ascorbate, benzenesulphonate, benzoate, cinnamate, citrate, embonate, enantate, fumarate, glutamate, glycolate, lactate, maleate, malonate, mandelate, methane-sulphonate, naphthalene-2-sulphonate, phthalate, salicylate, sorbate, stearate, succinate, tartrate or toluene-p-sulphonate salt.

8. The composition of claim 3 , wherein the composition comprises pridopidine salt, wherein the salt is hydrochloride salt.

9. The composition of claim 1 , in the form of a capsule, a tablet, a pill, a powder, a granule, a liquid solution or a liquid suspension.

10. The composition of claim 3 , in the form of a capsule, a tablet, a pill, a powder, a granule, a liquid solution or a liquid suspension.

11. The composition of claim 1 , in an oral dosage unit form.

12. The composition of claim 3 , in an oral dosage unit form.

13. The composition of claim 11 , wherein the oral dosage unit form comprises between 22.5-315 mg pridopidine.

14. The composition of claim 12 , wherein the oral dosage unit form comprises between 22.5-315 mg pridopidine.

15. The composition of claim 13 , wherein the oral dosage unit form comprises between 45-250 mg pridopidine.

16. The composition of claim 14 , wherein the oral dosage unit form comprises between 45-250 mg pridopidine.

17. The composition of claim 15 , wherein the oral dosage unit form comprises between 45-135 mg pridopidine.

18. The composition of claim 16 , wherein the oral dosage unit form comprises between 45-135 mg pridopidine.

19. The composition of claim 13 , wherein the oral dosage unit form comprises between 90-315 mg pridopidine.

20. The composition of claim 14 , wherein the oral dosage unit form comprises between 90-315 mg pridopidine.

21. The composition of claim 13 , wherein the oral dosage unit form comprises about 22.5 mg pridopidine, about 45 mg pridopidine, about 67.5 mg pridopidine, about 90 mg pridopidine, about 100 mg pridopidine, about 112.5 mg pridopidine, about 125 mg pridopidine, about 135 mg pridopidine, about 150 mg pridopidine, about 180 mg pridopidine, about 200 mg pridopidine, about 250 mg pridopidine, or about 315 mg pridopidine.

22. The composition of claim 14 , wherein the oral dosage unit form comprises about 22.5 mg pridopidine, about 45 mg pridopidine, about 67.5 mg pridopidine, about 90 mg pridopidine, about 100 mg pridopidine, about 112.5 mg pridopidine, about 125 mg pridopidine, about 135 mg pridopidine, about 150 mg pridopidine, about 180 mg pridopidine, about 200 mg pridopidine, about 250 mg pridopidine, or about 315 mg pridopidine.

23. A method of treating Huntington disease in a subject, comprising administering a pharmaceutical composition of claim 1 .

24. A method of treating Huntington disease in a subject, comprising administering a pharmaceutical composition of claim 3 .

25. The method of claim 23 , wherein the composition is administered once daily or more than once daily.

26. The method of claim 24 , wherein the composition is administered once daily or more than once daily.

Assignments (4)
CHANGE OF NAME Recorded Jan 5, 2020
From: PRILENIA THERAPEUTICS DEVELOPMENT LTD
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 051540/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2019
From: TEVA PHARMACEUTICAL INDUSTRIES LTD.
To: PRILENIA THERAPEUTICS DEVELOPMENT LTD
Reel/Frame 051369/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2019
From: CAMBREX KARLSKOGA AB,
To: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Reel/Frame 051300/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2019
From: SCHMIDT, MALLE; PARI, MALLE; LAOS, MARIT; MAASALU, ANTS; KALJUSTE, KALLE
To: CAMBREX KARLSKOGA AB,
Reel/Frame 051262/0684 →
Cited By (2)
US 12,551,474 US 12,702,662